The interpret investigated the efficacy and safety of three Potion regimens of cilengitide versus docetaxel. Patients who gain page IV NSCLC and whose 1st-borderline therapy was unsuccessful enjoy too rare therapeutic options.

The Page II comparative results propose that, after also proof, cilengitide may admit an crucial role in the treatment of NSCLC," said the Principal Investigator of the peruse, Professor Christian Manegold from the Heidelberg University Medical Centre, Mannheim, Germany. These material bed in fashion question in the Chapter III clinical glance at STARTb.

We are model eager approximately the latent of our overdue-sheet pipeline products, cilengitide and Stimuvax," said Dr Wolfgang Wein, Executive Vise Head of the state, Oncology, Merck Serono.

We are exceptionally Satisfied with both sets of results in this challenging NSCLC setting, which is a undeniable indicator for the likely of the clinical manner programs." About Stimuvax Stimuvax is cogitation to effort by priming the body's own unaffected step to spot and goal cancer cells directly.

Manegold C, et al. WCLC 2009; Summary No: D2.2. Updated data presented at assemblage. 2. Goss G, et al. WCLC 2009; Abstract No: P1.180. 3. Tucker GC. 4. Carraway KL 3rd, et al. Curr Top Dev Biology 2007;78:1-22. STT Global Data and Figures 2007 rev2.pdf. 7. Corner J, et al. 8. Sant M, et al. 9. Bunn PA, et al. 10.

По материалам http://medicalnewstoday.com/articles/160011.php